Table 4.
Primary Endpoint with an Analysis of Covariance Model
| Variable | n | Adjusted Mean (SE) | Adjusted Mean Difference (95% CI) | P value (Between-Group Difference) | |
|---|---|---|---|---|---|
| Teneligliptin Group (n = 8) | Control Group (n = 9) | ||||
| ΔEPC (/μL) | 16 | 0.29 (0.13) | 0.05 (0.13) | 0.24 (−0.16, 0.64) | 0.22 |
| ΔDPP-4 activity (μU/mL) | 16 | −544.9 (17.5) | 68.1 (17.5) | −612.9 (−669.8, −556.1) | <0.001 |
| ΔSDF-1α (pg/mL) | 16 | −700.0 (87.5) | 15.5 (87.5) | −715.6 (−983.0, −448.1) | <0.001 |
Abbreviations: EPC, endothelial progenitor cell; DPP-4, dipeptidyl peptidase-4; SDF-1α, stromal cell derived factor - 1α.